Showing results (21-30 of 33) with videos related to
Sort By:
Pageof 4
Journal of Neurology|January 27, 2018
Impact of D-dimer levels for short-term or long-term outcomes in cryptogenic stroke patientsTomohisa Nezu, Takaya Kitano, Satoshi Kubo, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 30, 2004
[Analysis of microsatellite instability and p53 LOH in advanced colorectal cancers--first report of the No. 3 protocol]Naohiro Tomita, Morito Monden, Nobuteru Kikkawa, et al.Japanese Journal of Clinical Oncology|October 7, 2004
The novel germline mutation of the hMLH1 gene in a case of suspected hereditary non-polyposis colorectal cancer (HNPCC) in a patient with no family history of cancerNaohiro Tomita, Mutsumi Fukunaga, Shu Okamura, et al.Stroke|May 2, 2009
Clinical-diffusion mismatch and benefit from thrombolysis 3 to 6 hours after acute strokeMartin Ebinger, Takeshi Iwanaga, Jane F Prosser, et al.Journal of the Neurological Sciences|February 5, 2022
Prior direct oral anticoagulant dosage and outcomes in patients with acute ischemic stroke and non-valvular atrial fibrillation: A sub-analysis of PASTA registry studyTakafumi Mashiko, Shigeru Fujimoto, Satoshi Suda, et al.Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|December 5, 2020
Cilostazol Addition to Aspirin could not Reduce the Neurological Deterioration in TOAST Subtypes: ADS Post-Hoc AnalysisJunya Aoki, Yasuyuki Iguchi, Takao Urabe, et al.Journal of the Neurological Sciences|March 31, 2020
Cilostazol uncovers covert atrial fibrillation in non-cardioembolic strokeJunya Aoki, Yasuyuki Iguchi, Takao Urabe, et al.Journal of the American Heart Association|July 27, 2019
Acute Aspirin Plus Cilostazol Dual Therapy for Noncardioembolic Stroke Patients Within 48 Hours of Symptom OnsetJunya Aoki, Yasuyuki Iguchi, Takao Urabe, et al.Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|June 13, 2021
Microbleeds and clinical outcome in acute mild stroke patients treated with antiplatelet therapy: ADS post-hoc analysisJunya Aoki, Yasuyuki Iguchi, Takao Urabe, et al.Stroke|January 26, 2017
YAMATO Study (Tissue-Type Plasminogen Activator and Edaravone Combination Therapy)Junya Aoki, Kazumi Kimura, Naomi Morita, et al.Pageof 4